‘Baraclude’ won the lawsuit of injunction in patent infringement against Dong-A
BMS Pharmaceutical Korea(President Hye-sun Park) announced on the 7th the company has won a lawsuit of injunction in patent infringement against Dong-A ST over ‘Baraclude® (generic name: entecavir),’ a chronic hepatitis B treatment.
According to BMS Pharmaceutical Korea, although there was a jud...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
